



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. ~~38~~163-0197.US

In re patent application of:
Jeffrey SCHLOM *et al.*

Confirmation No.: 5890

Serial No. 10/725,373

Art Unit: 1644

Filed: December 3, 2003

Examiner: DIBRINO, M.

For: AGONIST AND ANTAGONIST PEPTIDES OF CARCINOEMBRYONIC ANTIGEN
(CEA)

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A are documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

02/09/2007 SZEWDIE1 00000060 001641 10725373
02 FC:1006 100.00 DA

RELEVANCE

Reference C01 corresponds to Reference 19 in the list of references in the specification and is discussed in the specification at page 3, in the paragraph of lines 15-29; Reference C02 is Reference 29 and is discussed in the specification at page 5, in the paragraph of lines 5-32; Reference C03 corresponds to Reference 51 and is discussed in the specification at page 27, starting at line 9; Reference C04 corresponds to Reference 47 and is discussed in the specification at page 24 in the paragraph starting with line 3; Reference C05 corresponds to Reference 27 and is discussed in the specification at page 5, in the paragraph starting with line 5; Reference C06 corresponds to Reference 45 and is discussed in the specification at page 24 in the paragraph starting with line 3; Reference C07 corresponds to Reference 30 and discusses a system for identifying peptides that may trigger HLA-A2.1-restricted cytotoxic lymphocytes; Reference C08 corresponds to Reference 17 and is discussed in the specification at page 3, in the paragraph beginning with line 15; and Reference C09 corresponds to Reference 20, which is discussed in the specification at page 3, in the paragraph starting with line 3.

TIMING/FEE


The instant Information Disclosure Statement is being filed after the mailing of a first Office action on the merits but before the mailing date of either (1) a final action under §1.113; (2) a notice of allowance under §1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the required fee in the amount of \$180.00 in accordance with 37 CFR §1.17(p), along with any deficiency or to credit any overpayment, to Deposit Account No. 08-1641.

Applicants respectfully request that the listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,


Date: February 8, 2007

Heller Ehrman LLP
1717 Rhode Island Avenue, NW
Washington, D.C. 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020



Patricia D. Granados
Reg. No. 33,683
Attorney for Applicant

Customer No. 44991



+

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/725,373
Filing Date	December 3, 2003
First Named Inventor	Jeffrey SCHLOM et al.
Group Art Unit	1644
Examiner Name	Marianne Nmn Dibrino
Attorney Docket Number	38163-0197

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C01	ALEXANDER B.H. BAKKER et al., "Analogues of CTL Epitopes with Improved MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wild-Type Epitope", Int. J. Cancer, 1997, pp. 302-309, Vol. 70	
	C02	YU ZHEN CHEN et al., "Response of a Human T Cell Clone to a Large Panel of Altered Peptide Ligands Carrying Single Residue Substitutions in an Antigenic Peptide", The Journal of Immunology, 1996, pp. 3783-3790	
	C03	WEISAN CHEN et al., "CTL Recognition of an Altered Peptide Associated with Asparagine Bond Rearrangement", The Journal of Immunology, 1996, pp. 1000-1005	
	C04	RICHARD D. ENGLAND et al., "Molecular Analysis of a Heteroclitic T Cell Response to the Immunodominant Epitope of Sperm Whale Myoglobin", The Journal of Immunology, 1995, pp. 4295-4306	
	C05	STEPHEN C. JAMESON et al., "T Cell Receptor Antagonists and Partial Agonists", Immunity, January, 1995, pp. 1-11, Vol. 2	
	C06	TAKAKO MATSUOKA et al., "Altered TCR Ligands Affect Antigen-Presenting Cell Responses", The Journal of Immunology, 1996, pp. 4837-4843	
	C07	HANS W. NIJMAN et al., "Identification of peptide sequences that potentially trigger HAL-A2.1-restricted cytotoxic T. lymphocytes", Eur. J. Immunol. 1993, pp. 1215-1219, Vol. 23	
	C08	MARIA R. PARKHURST et al., "Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues", The Journal of Immunology, 1996, pp. 2539-2548	
	C09	REBECCA R. POGUE et al., "Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and <i>in vitro</i> Immunogenicity", Proc. Natl. Acad. Sci. USA, August 1995, pp. 8166-8170, Vol. 92	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.